Control Bionics Ltd. (AU:CBL)
ASX:CBL
Top Page
Control Bionics Ltd.
(Sydney:CBL)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.05
▼(-10.00% Downside)
Action:ReiteratedDate:03/05/26
The score is held back primarily by weak financial quality—ongoing losses and negative operating cash flow outweigh solid revenue growth and a low-leverage balance sheet. Technicals are mixed with modest trend support but soft momentum, while valuation is constrained by negative earnings and no dividend yield provided.
Positive Factors
Revenue Growth
A recurring top-line expansion of ~16% indicates durable demand and product adoption in its core assistive-tech niche. Sustained revenue growth, if maintained, supports scale benefits and the potential to leverage fixed-cost base to improve margins over the next several quarters.
Negative Factors
Negative Operating Cash Flow
Operating cash flow is negative and free cash flow has declined, signaling the business is not converting revenue into cash. This structural cash-generation shortfall increases reliance on external funding, constrains reinvestment capacity, and raises execution risk over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A recurring top-line expansion of ~16% indicates durable demand and product adoption in its core assistive-tech niche. Sustained revenue growth, if maintained, supports scale benefits and the potential to leverage fixed-cost base to improve margins over the next several quarters.
Read all positive factors
Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$24.72M
Dividend YieldN/A
Average Volume (3M)173.99K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue Growth14.84%
EPS Growth39.64%
CountryAU
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.01
Shares Outstanding411,961,880
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Control Bionics Ltd. Business Overview & Revenue Model
Company Description
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and Neur...
How the Company Makes Money
null...
Control Bionics Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.07M | 6.14M | 5.35M | 5.64M | 4.50M | 4.09M |
| Gross Profit | 326.42K | 4.11M | 3.90M | 3.71M | -2.91M | 2.50M |
| EBITDA | -5.50M | -5.14M | -5.01M | -5.14M | -5.92M | -3.40M |
| Net Income | -6.50M | -6.11M | -5.91M | -5.63M | -6.11M | -3.55M |
Balance Sheet | ||||||
| Total Assets | 9.93M | 8.23M | 9.03M | 8.70M | 13.44M | 18.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.06M | 672.66K | 980.76K | 935.50K | 5.21M | 12.33M |
| Total Debt | 258.10K | 435.40K | 961.74K | 128.50K | 284.82K | 14.87K |
| Total Liabilities | 2.20M | 2.72M | 2.76M | 1.58M | 1.51M | 1.19M |
| Stockholders Equity | 7.73M | 5.51M | 6.27M | 7.15M | 11.92M | 17.16M |
Cash Flow | ||||||
| Free Cash Flow | -4.46M | -4.57M | -5.38M | -4.98M | -5.75M | -4.04M |
| Operating Cash Flow | -4.13M | -4.27M | -4.91M | -4.53M | -5.60M | -3.99M |
| Investing Cash Flow | -704.37K | -744.78K | -473.09K | -457.54K | -147.74K | -53.40K |
| Financing Cash Flow | 6.93M | 4.63M | 5.43M | 706.43K | -87.33K | 14.92M |
Control Bionics Ltd. Technical Analysis
Neutral
0.06
Price Trends
0.06
Negative
0.06
Negative
0.05
Positive
Market Momentum
>-0.01
Negative
50.25
Neutral
96.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.25 is Neutral, neither overbought nor oversold. The STOCH value of 96.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CBL.
Control Bionics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$54.28M | -9.32 | -417.72% | ― | -34.06% | 75.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$24.72M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
43 Neutral | AU$3.12M | -0.88 | -358.43% | ― | -30.80% | -38.95% | |
41 Neutral | AU$13.43M | -0.50 | 459.94% | ― | -2.82% | 32.47% | |
40 Underperform | AU$25.93M | -4.09 | -58.40% | ― | -7.20% | 28.70% |
* Healthcare Sector Average
AU:CBL
Control Bionics Ltd.
0.06
<0.01
17.65%
AU:UCM
Uscom Limited
0.01
-0.02
-55.56%
AU:HMD
HeraMED Ltd.
0.05
0.03
213.33%
AU:AT1
Atomo Diagnostics Ltd.
0.03
0.01
60.00%
AU:ADR
Adherium Ltd.
―
―
―
Control Bionics Ltd. Corporate Events
Control Bionics Secures First U.S. LOI for iOS Speech Device Program
Mar 25, 2026
Control Bionics has signed its first U.S. Letter of Intent for an iOS-based speech generating device program, stemming from its recent partnership with NextLevel. The non-binding agreement with a U.S. customer signals planned annual purchases of d...
Control Bionics Wins German Reimbursement Listing for NeuroNode
Mar 3, 2026
Control Bionics has secured formal inclusion of its NeuroNode device in Germany’s Statutory Health Insurance Medical Aids Directory, confirming that the system meets the country’s regulatory, safety, quality and clinical requirements f...
Control Bionics Director Stephen Rix Increases Shareholding via On-Market Purchase
Mar 2, 2026
Control Bionics director Stephen Rix has increased his direct and indirect holding in the company, primarily via Windward Capital Pty Limited, through an on-market purchase of 587,632 ordinary shares on 27 February 2026. The acquisition, valued at...
Control Bionics strikes capital-light US deal to expand iOS speech device range
Feb 25, 2026
Control Bionics’ U.S. subsidiary has entered an exclusive joint venture-style agreement with NextLevel Assistive Technology to manufacture, assemble, and distribute new UnoTouch Omni and Active iOS-based speech-generating devices in the Unit...
Control Bionics Swings to Deeper Half-Year Loss as Revenue Falls, Secures Full Control of Neuro Elite
Feb 25, 2026
Control Bionics Limited reported a 26% decline in revenue to $2.82 million for the half-year ended 31 December 2025, alongside a sharp increase in net loss after tax to $3.61 million, compared with the prior corresponding period. No dividends were...
Control Bionics to Brief Investors on Interim Results and EMG Growth Strategy
Feb 25, 2026
Control Bionics Limited will host an investor webinar on 26 February 2026, following the release of its interim financial report and Appendix 4D, with CEO Jeremy Steele and CFO Shannon Boothroyd presenting a business update and taking questions fr...
Control Bionics Secures PRC-Saltillo Deal to Expand NeuroNode Access in US
Jan 29, 2026
Control Bionics has signed a two-year US distribution agreement with AAC specialist PRC-Saltillo for its NeuroNode technology, formalising a relationship that has already seen PRC staff trained, devices used in trials and demonstrations, and insur...
Control Bionics Raises Capital, Secures Tobii Deal and Apple BCI Integration in Strategically Pivotal Quarter
Jan 27, 2026
Control Bionics reported a strategically significant December 2025 quarter highlighted by a $3.8 million capital raise to fund commercial, regulatory and manufacturing initiatives across its core platforms, including NeuroNode and NeuroStrip, in t...
Control Bionics Strikes U.S. Pilot Deal With Tobii Dynavox for NeuroNode AAC Technology
Jan 26, 2026
Control Bionics has signed an agreement with AAC market leader Tobii Dynavox to run a six‑month pilot in five northwestern U.S. states, under which Tobii Dynavox will evaluate offering Control Bionics’ NeuroNode technology alongside it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.